Meta-analysis of the effects of CYP3A5*3 gene polymorphisms on tacrolimus blood concentration and effectiveness in Chinese patients with membranous nephropathy.

OBJECTIVE

The study aimed to systematically evaluate the relationship between CYP3A5*3 gene polymorphisms and the blood concentration and effectiveness of tacrolimus (TAC) in patients with membranous nephropathy (MN).

METHODS

PubMed, Cochrane Library, Embase, Web of Science, China Biomedical, China National Knowledge Infrastructure, Wanfang, Vipshop, ReadShow, Clinical Trials Registry, and other databases were searched. Studies on the relationship between CYP3A5*3 gene polymorphism and TAC blood concentration in MN patients were collected, and meta-analysis was performed using Stata 16 software.

RESULTS

A total of eight publications were included in the study, including 498 MN patients. CYP3A53 gene polymorphisms are associated with tacrolimus blood levels in patients with MN. The results of the relationship between CYP3A53 genotype polymorphisms and tacrolimus blood trough concentrations of the AA + AG genotype were lower than those of the GG genotype at ≤1 month [WMD = -2.08, 95% CI (-2.57, -1.59), < 0.001] and 1-6 months [WMD = -0.63, 95% CI (-0.98, -0.27), < 0.001]; however, they were not statistically significant at ≥6 months ( = 0.211). Furthermore, the subgroup analysis revealed that the dose-adjusted concentration of tacrolimus (C0/D) of the AA + AG genotype was lower than that of the GG genotype at ≤1 month [SMD = -1.93, 95% CI (-2.79, -1.08), < 0.001], 1-6 months [SMD = -2.25, 95% CI (-2.71, -1.79), < 0.001], and ≥6 months [SMD = -2.36, 95% CI (-2.86, -1.86), < 0.001]. In addition, there was no statistically significant difference in effectiveness between the two groups at 3, 6, and 12 months of TAC administration ( > 0.05).

CONCLUSION

Serum TAC concentrations in MN patients were correlated with CYP3A53 genotype polymorphisms. Detection of the CYP3A53 genotype before the administration of TAC may provide some clinical value for optimizing the treatment of MN patients.

SYSTEMATIC REVIEW REGISTRATION

https://inplasy.com/, identifier [INPLASY202430083].